Related Experiment Video
Updated: Jul 12, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcal Pure Polysaccharide Vaccination in Pediatric Patients With Chronic Heart Disease
Insights
Pneumococcal polysaccharide vaccine-23 (PPSV23) use was low in children with chronic heart disease (CHD). Many missed vaccination opportunities suggest improved strategies are needed for this high-risk group.
Area of Science:
- Pediatric Cardiology
- Vaccinology
- Public Health
Background:
- Children with chronic heart disease (CHD) are at increased risk for pneumococcal infections.
- Pneumococcal polysaccharide vaccine-23 (PPSV23) is recommended for certain high-risk pediatric populations.
- Vaccination rates and missed opportunities for PPSV23 in pediatric CHD patients are not well-characterized.
Purpose of the Study:
- To describe the utilization of pneumococcal polysaccharide vaccine-23 (PPSV23) in pediatric patients diagnosed with chronic heart disease (CHD).
- To identify missed opportunities for PPSV23 vaccination in this high-risk cohort.
Main Methods:
- A single-center retrospective cohort study was conducted.
- Included patients were aged 2-18 years with a diagnosis of CHD.
- Data collected included PPSV23 vaccination status, clinic visit frequency, and incidence of pneumonia.
Main Results:
- 392 pediatric patients with CHD were included; mean age was 8.8 years.
- Only 10.2% (40 patients) had documented PPSV23 vaccination.
- Patients had a median of three clinic visits in 2019, indicating potential missed opportunities.
Conclusions:
- PPSV23 vaccination rates are low among pediatric patients with CHD.
- Numerous missed opportunities for vaccination were documented.
- The lack of routine inclusion of PPSV23 in pediatric schedules may contribute to low uptake.
Introduction:
This study aimed to describe pneumococcal polysaccharide vaccine-23 (PPSV23) vaccination use in high-risk pediatric patients with chronic heart disease (CHD).
Method:
This was a single-center retrospective cohort study. Patients were included if they were aged 2-18 years and were diagnosed with CHD. The primary outcome was PPSV23 vaccination. Secondary outcomes included missed opportunities and the incidence of infections.
Results:
Three hundred ninety-two patients were included; the mean age was 8.8 years. Only 40 patients (10.2%) had documentation of PPSV23 vaccination. Patients had a median number of three clinic visits in 2019. There were 114 cases of pneumonia documented in patients before receiving PPSV23 and one case reported after PPSV23 vaccination.
Discussion:
PPSV23 vaccination in high-risk pediatric patients with CHD was low, with many documented missed opportunities for vaccination. This may be attributed to the PPSV23 not being a routine vaccination on the pediatric schedule.
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Rheumatic Heart Disease III: Medical Management
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cardiomyopathy V: Interprofessional Care

